Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update [0.03%]
与利妥昔单抗相关的进行性多灶性白质脑病：20年回顾更新
Charles L Bennett,Bartlett Witherspoon,Kenneth R Carson
Charles L Bennett
Progressive multifocal leukoencephalopathy (PML) is a John-Cunningham virus-related central nervous system that is rarely observed in persons treated with the anti-CD20 monoclonal antibody, rituximab. ...
Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen [0.03%]
丹麦的腐败：哥本哈根发生的肾源性系统纤维症病发案例
Charles L Bennett,Bartlett Witherspoon,Kenneth R Carson et al.
Charles L Bennett et al.
More than half of all serious adverse drug reactions are identified seven years after FDA approval. One recent and unusual example involves a syndrome initially termed nephrogenic dermatopathic fibrosis, and then called nephrogenic systemic...
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions [0.03%]
严重药物不良反应上报的体制障碍与潜在问题
Matthew A Taylor,Ashley C Godwin,Shamia Hoque et al.
Matthew A Taylor et al.
About 1-10% of all serious adverse drug reactions (sADRs) are reported to the Food and Drug Administration (FDA) ( Moore T, Bennett C. Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug A...
Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration [0.03%]
将研究转化为卫生政策：民众向食品和药物管理局提出的请愿个案体验
Paul Ray,Charles L Bennett
Paul Ray
Translating research findings into policy is important. Health policy researchers often testify before Congressional subcommittees and provide background on health policy issues. A rarely used, but important, tool for facilitating translati...
Policing of Drug Safety Information Dissemination Under the False Claims Act [0.03%]
根据《虚假索赔法》对药物安全信息传播的监管
Brian Chen,Tony Yang,Charles L Bennett
Brian Chen
On July 25, 2017, the second largest multi-million dollar settlement was pursued with the assistance of the Department of Justice and alleging inappropriate marketing strategies utilized by the pharmaceutical industry came to an end. ...
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions [0.03%]
美国的生物类似药Epoetin：来自南方网络不良反应的观点
Sumimasa Nagai,Bartlett Witherspoon,Chadi Nabhan et al.
Sumimasa Nagai et al.
Biosimilar drugs, close copies of patented biologicals, are intended to provide access to less expensive, highly similar versions of reference (previously approved) biological agents (Kozlowski et al. in N Engl J Med 365:385-388, 2011). The...
Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years [0.03%]
氟喹诺酮相关残疾及其他氟喹诺酮类严重不良事件：近年来出现的意外毒性反应
Charles L Bennett,Oscar Champigneulle,Andrew Bennett et al.
Charles L Bennett et al.
This study describes cases of individuals who report adverse events following consumption of the most commonly prescribed fluoroquinolone (FQ) antibiotics: ciprofloxacin, levofloxacin, or moxifloxacin. Fluoroquinolone (FQ) antibiotics are s...
Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies [0.03%]
双特异抗体在血液系统恶性肿瘤中的临床开发和治疗应用
Priya Hays
Priya Hays
Bispecific antibodies are composed of two monoclonal antibodies that engage T cells with tumor cell antigens and lead to tumor cell lysis. The most common types fall into the category of bispecific T cell engagers, or BiTEs, that have the c...
The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells [0.03%]
CAR-T细胞重编程肿瘤微环境的单细胞水平视角
Sanxing Gao,Ryohichi Sugimura
Sanxing Gao
The tumor microenvironment (TME) is a complex milieu consisting of lymphoid cells, myeloid cells, fibroblasts, and multiple molecules, which play a key role in tumor progression and immunotherapy. TME is characterized by immune-suppressive ...
Off-the-Shelf Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells [0.03%]
由人类多能干细胞制备即用型嵌合抗原受体免疫细胞
Handi Cao,Ryohichi Sugimura
Handi Cao
Autologous chimeric antigen receptor (CAR) T cells have expanded the scope and therapeutic potential of anti-cancer therapy. Nevertheless, autologous CAR-T therapy has been challenging due to labor some manufacturing processes for every pat...